$1.33
-0.01 (-0.75%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CHRS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
17 interventional · 1 observational · 5 with posted results
Held by 9 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, Hudson Bay Capital Management LP, AQR CAPITAL MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, +4 more) · FINRA short interest 53.6 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study of CHS-1000 in Participants With Advanced or Metastatic Solid TumorsNCT06389526Number of Participants with Treatment-Emergent Adverse Events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1 | Not yet recruiting | Biological: CHS-1000, Toripalimab | Advanced or Metastatic Solid Tumors | 48 | 2028-05-30 | in 649 d | 2024-09-19 |
| A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid TumorsNCT06657144Number of Participants With Treatment-emergent Adverse Events (TEAEs)Randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: CHS-114, Toripalimab, 5 Fluorouracil, Cisplatin | Metastatic Solid Tumor, Advanced Solid Tumor | 154 | Jan 2028 | ≤ 529 d | 2026-07-15 |
| A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal CancerNCT06457503Objective Response Rate (ORR) assessed by a Blinded Independent Central Review (BICR) Committee according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1Open-label · Treatment | Phase 4 | Recruiting | Drug: Toripalimab, Cisplatin, Gemcitabine, Carboplatin | Nasopharyngeal Cancer Recurrent | 100 | Dec 2027 | ≤ 498 d | 2026-07-30 |
| A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular CarcinomaNCT06679985Number of Participants with Treatment-emergent Adverse Events (TEAEs)Randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Casdozokitug, Toripalimab, Bevacizumab | Hepatocellular Carcinoma | 72 | Sep 2027 | ≤ 406 d | 2026-07-15 |
| Study of CHS-114 in Participants With Advanced Solid TumorsNCT05635643[Arms 1a, 1b, and 2] Rate of Dose Limiting Toxicity (DLT)Randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: CHS-114, toripalimab | Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma | 87 | 2026-09-30 | in 41 d | 2026-08-12 |
| Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular CarcinomaNCT05359861Nature, frequency, and severity of adverse events (AEs) per NCI CTCAE version 5.0 or higherRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: SRF388, Atezolizumab, Bevacizumab, Placebo | Hepatocellular Carcinoma | 30 | 2025-06-30actual | — | 2026-06-29 |
| Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid TumorsNCT04374877[Part A] Dose Limiting Toxicity (DLT)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: CHS-388, Pembrolizumab, Toripalimab | Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer | 145 | 2025-05-28actual | — | 2026-07-15 |
| Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid TumorsNCT05757492Assessment of the number of participants with treatment-emergent adverse events (TEAEs) receiving CHS-006 administered in combination with toripalimabRandomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The study was terminated for strategic reasons (not for safety concerns) | Drug: CHS-006 (anti-TIGIT), toripalimab (anti-PD-1) | Advanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma | 22 | 2024-07-31actual | — | 2025-05-01 |
| Study of SRF617 in Patients With Advanced Solid TumorsNCT04336098Dose Limiting Toxicity of SRF617Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: SRF617, Gemcitabine, Albumin-Bound Paclitaxel, Pembrolizumab | Advanced Solid Tumor | 85 | 2023-08-25actual | — | 2024-06-04 |
| Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate CancerNCT05177770results2024-05-17Number of Participants With ResponseOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: The study was terminated for strategic reasons, not due to any safety concerns. | Drug: SRF617, etrumadenant, zimberelimab | Metastatic Castration-resistant Prostate Cancer, Prostate Cancer | 16 | 2023-04-05actual | — | 2025-05-08 |
| An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving UdenycaNCT04662892observationalThe incidence of FN in real-world outcome setting | — | Unknown status | Drug: Pegfilgrastim-Cbqv | Febrile Neutropenia, Non-myeloid Malignancy | 200 | 2022-11-01 | — | 2020-12-23 |
| A Long Term Safety Extension Study (CHS-0214-05)NCT02486939results2018-12-27Durability of Response (Maintenance of an ACR20 Response or Greater), Which Was Measured at Each Visit in Subjects of RAOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: CHS-0214 | Rheumatoid Arthritis, Plaque Psoriasis | 359 | Sep 2017actual | — | 2018-12-27 |
| Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With NeulastaNCT02650973Bioequivalence as measured by PK and PDRandomized · Single-masked | Phase 1 | Completed | Drug: CHS-1701, Pegfilgrastim | Healthy | 122 | Jun 2016actual | — | 2016-08-01 |
| Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque PsoriasisNCT02489227results2019-10-18Difference Between the Percentage of Subjects in Each Treatment Group Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI-75) at Week 12Randomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: CHS-1420, Adalimumab | Plaque Psoriasis | 545 | 2016-05-06actual | — | 2020-04-08 |
| Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta®NCT02418104To assess the immunogenicity of CHS-1701 compared to NeulastaRandomized · Triple-masked | Phase 1 | Completed | Drug: CHS-1701, Pegfilgrastim (Neulasta) | Immunity, Humoral | 303 | Dec 2015actual | — | 2016-01-07 |
| Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)NCT02115750results2019-06-26ACR-20 - 20% Improvement According to American College of Rheumatology CriteriaRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Etanercept, CHS-0214 | Rheumatoid Arthritis | 647 | Oct 2015actual | — | 2019-06-26 |
| Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® (Pegfilgrastim)NCT02385851Biosimilarity as measured by absolute neutrophil count (ANC)Randomized · Triple-masked | Phase 1 | Completed | Drug: CHS-1701, Pegfilgrastim | Bioequivalence | 116 | Jul 2015actual | — | 2015-08-13 |
| Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)NCT02134210results2019-05-13Proportion of Subjects Achieving PASI-75(75% Improvement in Psoriasis Area and Severity Index) From Baseline at Week 12Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Etanercept, CHS-0214 | Plaque Psoriasis | 521 | 2015-07-27actual | — | 2019-06-28 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19